Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
Bello E, Brich S, Craparotta I, Mannarino L, Ballabio S, Gatta R, Marchini S, Carrassa L, Matteo C, Sanfilippo R, Gronchi A, Casali PG, Pilotti S, D'Incalci M, Frapolli R. Bello E, et al. Among authors: frapolli r. Br J Cancer. 2019 Sep;121(6):464-473. doi: 10.1038/s41416-019-0550-2. Epub 2019 Aug 14. Br J Cancer. 2019. PMID: 31409911 Free PMC article.
Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.
Gambacorti-Passerini CB, Rossi F, Verga M, Ruchatz H, Gunby R, Frapolli R, Zucchetti M, Scapozza L, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, D'Incalci M, Corneo G. Gambacorti-Passerini CB, et al. Among authors: frapolli r. Blood Cells Mol Dis. 2002 May-Jun;28(3):361-72. doi: 10.1006/bcmd.2002.0526. Blood Cells Mol Dis. 2002. PMID: 12367580 Clinical Trial.
IDN 5390: an oral taxane candidate for protracted treatment schedules.
Pratesi G, Laccabue D, Lanzi C, Cassinelli G, Supino R, Zucchetti M, Frapolli R, D'Incalci M, Bombardelli E, Morazzoni P, Riva A, Zunino F. Pratesi G, et al. Among authors: frapolli r. Br J Cancer. 2003 Mar 24;88(6):965-72. doi: 10.1038/sj.bjc.6600784. Br J Cancer. 2003. PMID: 12644838 Free PMC article.
Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.
Tognon G, Frapolli R, Zaffaroni M, Erba E, Zucchetti M, Faircloth GT, D'Incalci M. Tognon G, et al. Among authors: frapolli r. Cancer Chemother Pharmacol. 2004 Jan;53(1):89-90. doi: 10.1007/s00280-003-0704-y. Epub 2003 Oct 28. Cancer Chemother Pharmacol. 2004. PMID: 14586558 No abstract available.
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients.
Fruscio R, Lissoni AA, Frapolli R, Corso S, Mangioni C, D'Incalci M, Zucchetti M. Fruscio R, et al. Among authors: frapolli r. Cancer Chemother Pharmacol. 2006 Sep;58(3):319-25. doi: 10.1007/s00280-005-0160-y. Epub 2005 Dec 13. Cancer Chemother Pharmacol. 2006. PMID: 16362296 Clinical Trial.
Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.
Frapolli R, Marangon E, Zaffaroni M, Colombo T, Falcioni C, Bagnati R, Simone M, D'Incalci M, Manzotti C, Fontana G, Morazzoni P, Zucchetti M. Frapolli R, et al. Drug Metab Dispos. 2006 Dec;34(12):2028-35. doi: 10.1124/dmd.106.012153. Epub 2006 Sep 8. Drug Metab Dispos. 2006. PMID: 16963486
85 results